EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS • First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range • First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million • Updates FY 2024 guidance GAITHERSBURG, Md., May 1, 2024—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President an ...